STOCK TITAN

Graf Acquisition IV Stock Price, News & Analysis

GFOR NYSE

Company Description

Graf Acquisition Corp. IV (Symbol: GFOR) is a blank check company incorporated in Delaware. The company’s primary purpose is to execute mergers, capital stock exchanges, asset acquisitions, stock purchases, reorganizations, or similar business combinations with one or more businesses. Graf focuses on industrial companies, particularly those involved in diversified industrial manufacturing, technology, distribution, and service sectors within the United States and Canada.

Graf has recently been active in pursuing a significant business combination with NKGen Biotech, Inc., a clinical-stage biotechnology company specializing in innovative natural killer cell therapies. NKGen develops and commercializes both autologous and allogeneic CAR-NK cell therapies, positioning itself at the forefront of cutting-edge biotechnological advancements. Headquartered in Santa Ana, California, NKGen’s mission aligns with Graf's strategic focus, thus making this merger a vital step for both companies.

On September 11, 2023, Graf announced the adjournment of its Special Meeting intended for approving the business combination with NKGen. Despite having received sufficient proxy votes to approve the proposals, the meeting was postponed to September 13, 2023, to allow more time to secure additional financing. The meeting was again rescheduled for September 20, 2023, and then to September 25, 2023, to meet the necessary financial conditions, which include obtaining at least $50 million in additional funding. In a recent development, NKGen waived this $50 million minimum cash condition, indicating strong confidence in the successful closure of the merger.

Graf's financial condition remains robust, thanks to its strategic partnerships and experienced management team. The company’s executive officers and directors actively participate in the solicitation of proxies to ensure that all stockholders are well-informed and their votes are accurately represented. The company continues to engage with stockholders through various communication channels, including proxy solicitation services provided by Morrow Sodali LLC.

Graf has filed a comprehensive registration statement on Form S-4 with the SEC, detailing the proposed business combination. Stockholders are encouraged to review the definitive proxy statement/prospectus available on the SEC's website for detailed information about the merger and its implications.

Overall, Graf Acquisition Corp. IV remains committed to achieving its goal of combining with industrial and technology-driven businesses, leveraging its financial strength to create lasting value for its stockholders.

Stock Performance

$—
0.00%
0.00
Last updated:
- %
Performance 1 year
$86.1M
Market Cap
10.4M
Shares outstanding

SEC Filings

No SEC filings available for Graf Acquisition IV.

Financial Highlights

Revenue (TTM)
Net Income (TTM)
Diluted EPS (TTM)
Operating Cash Flow
Net Profit Margin
Oper. Profit Margin

Upcoming Events

Frequently Asked Questions

What is the market cap of Graf Acquisition IV (GFOR)?

The market cap of Graf Acquisition IV (GFOR) is approximately 86.1M.

What is Graf Acquisition Corp. IV?

Graf Acquisition Corp. IV is a blank check company formed to execute mergers, capital stock exchanges, asset acquisitions, stock purchases, reorganizations, or similar business combinations.

What is the focus of Graf Acquisition Corp. IV?

Graf focuses on industrial companies involved in diversified industrial manufacturing, technology, distribution, and service sectors in the United States and Canada.

What is the latest news about Graf Acquisition Corp. IV?

Graf is currently in the process of executing a business combination with NKGen Biotech, a clinical-stage biotechnology company specializing in natural killer cell therapies.

Why was the Special Meeting adjourned?

The Special Meeting was adjourned to allow additional time for obtaining necessary financing to meet the conditions of the business combination with NKGen Biotech.

Who is NKGen Biotech?

NKGen Biotech is a clinical-stage biotechnology company focused on developing and commercializing innovative autologous, allogeneic, and CAR-NK natural killer cell therapies.

When will the Special Meeting reconvene?

The Special Meeting is scheduled to reconvene on September 25, 2023, at 4:00 p.m. Eastern Time.

What should stockholders do if they have not voted yet?

Stockholders who have not yet voted are encouraged to vote as soon as possible. Those who have already voted and do not want to change their vote need not take further action.

Where can stockholders find more information about the proposed business combination?

Stockholders can find detailed information on the SEC's website or by requesting documents from Graf Acquisition Corp. IV at their provided address.

What is the purpose of the proxy solicitation?

The proxy solicitation aims to ensure all stockholders are well-informed and their votes are accurately represented regarding the proposed business combination with NKGen.

How can stockholders get assistance with voting?

Stockholders needing assistance with voting can contact the company’s proxy solicitor, Morrow Sodali LLC, via phone or email as provided in the announcements.